The Food and Drug Administration (FDA) has approved Lundbeck’s Carnexiv™ (carbamazepine) injection as a short-term replacement therapy for oral carbamazepine formulations in adults with certain seizure types when oral administration is temporarily not feasible. Carnexiv will be the first available intravenous (IV) formulation of the antiepileptic drug (AED) carbamazepine, and Lundbeck plans to make it commercially available in the US in early 2017. Carnexiv is a short-term (7 days) intravenous replacement therapy for oral carbamazepine formulations that provides continuity of care for adult patients who are unable to take carbamazepine by mouth and have seizure types: partial seizures with complex symptomatology; generalized tonic-clonic seizures; and mixed seizure patterns.
March 25, 2019
Pregabalin Effective in Reducing Seizure Frequency in Children with Focal Seizures: A Randomized Controlled Trial
According to this study, pregabalin 10 mg/kg/d showed effectiveness in reducing seizure frequency in children with focal seizures vs placebo; both doses of pregabalin were generally safe and well tolerated.
March 18, 2019
Study Finds Antiepileptic Drug Withdrawal Increases the Likelihood for Epileptic Seizures but Does Not Prolong Seizure Duration
Although anti-epileptic drug withdrawal increases the likelihood for epileptic seizures, it did not prolong the seizure duration, nor did it increase the rate of secondary generalization in this study.